GoQuick Dual stands on two histories that took a century to meet: freeze-drying, which made fragile drugs shelf-stable, and the dual-chamber device, which made a dry drug giveable in one motion. These are the names and the years. Where a claim is Panacea's own, we say so.
German histologist Richard Altmann devises a method to freeze-dry plant and animal tissues — the first recorded modern freeze-drying. It goes virtually unnoticed for four decades.
American researcher L. F. Shackell independently creates the vacuum freeze-drying chamber using an electrical pump — the apparatus every pharmaceutical lyophilizer descends from. Patents by Tival (1927) and Elser (1934) improve the freezing and condenser steps.
Blood plasma and penicillin are needed at the front without refrigerated transport. Freeze-drying is developed as a commercial technique to render both chemically stable without refrigeration — and the lyophilized injectable, a dry cake in a sealed vial, is born. So is its shadow: the vial must be reconstituted by hand before use.
Two-compartment delivery quietly becomes established practice: dual-chamber syringes and cartridges carry reconstituted growth hormone, emergency glucagon and lyophilized vaccines — powder in one chamber, diluent in the other, a bypass between them, and a single plunger stroke that mixes and delivers. The design exists precisely because separate-vial reconstitution is error-prone at the moment of care.
Established industry precedent, as described in Panacea Bio Chem's published GoQuick Dual materials
A hospital-pharmacy economic evaluation of ready-to-dilute thiotepa (Tepylute) versus its lyophilized powder form models a full year of preparation: the ready-to-dilute format saves time, reduces wastage and lowers clinical risk from preparation errors — the paper cites a study in which 15% of lyophilized thiotepa doses were prepared out of tolerance.
Ryan O. et al., Clinicoecon Outcomes Res (2026) — PubMed 41859240
A randomized, controlled, triple-blinded trial compares a ready-to-use abobotulinumtoxinA against the lyophilized onabotulinumtoxinA powder that requires reconstitution — finding comparable efficacy and durability. Most botulinum toxin formulations on the market are still lyophilized powders; the industry's direction of travel is away from the manual mixing step.
Gonçalves J.R. et al., J Cosmet Dermatol (2026) — PubMed 41889091
Panacea takes the dual-chamber precedent and rebuilds it around its own freeze-drying stack: a pre-filled dual-chamber cartridge in which the lyophilized cake and its solvent stay apart until one action breaches the septum and reconstitutes the dose at the point of use. Panacea states the cartridges are assembled on its proprietary VANA machine — enabling multi-layer lyophilization, vacuum-sealed chambers and airless micro-volume transfer — and pair with the EZnject auto-injector kit for end-user delivery. Internal geometry, sequencing and materials remain Panacea intellectual property.
Panacea Bio Chem's own published statements (goquickdual.com) · internal mechanism not disclosed